糖类抗原125消除常数K对复发性卵巢癌患者预后评估的临床价值研究OA

Objective To investigate the predictive value of the CA125 elimination rate constant K(KELIM)for chemotherapy sensitivity and its clinical significance in prognostic assessment among patients with recurrent ovarian cancer(ROC)receiving standard treatment.Methods A retrospective analysis was conducted on the clinical data of 311 patients with advanced epithelial ovarian carcinoma admitted to the First Affiliated Hospital of Chongqing Medical University between January 2015 and December 2022,including 121 patients in the recurrence cohort.The optimal cut-off value of KELIM for predicting chemotherapy sensitivity was determined using the receiver operating characteristic(ROC)curve.Patients were divided into favorable and unfavorable KELIM groups.The platinum-free interval(PFI),progression-free survival(PFS),and overall survival(OS)were compared between the two groups.Independent prognostic factors were identified using the Cox regression model.Results In the recurrence cohort,the area under the ROC curve(AUC)of KELIM for predicting chemotherapy sensitivity was 0.696(P＜0.001),with an optimal cut-off value of 0.82.The median PFI was significantly longer in the favorable KELIM group than in the unfavorable group(9.4 months vs.5.0 months,P＜0.001).Both median PFS(13.4 months vs.10.7 months,P=0.006)and median OS(77.3 months vs.50.6 months,P＜0.001)were higher in the favorable KELIM group than in the unfavorable KELIM group.Multivariate analysis confirmed that a KELIM≥0.82 was an independent predictive factor for OS.Conclusion In the population with recurrent ovarian cancer,KELIM serves as an effective indicator for predicting chemotherapy sensitivity and assessing prognosis,potentially aiding in the early identification of platinum-resistant patients.